Skip to Content

Omalizumab

In the US, Omalizumab (omalizumab systemic) is a member of the drug class other immunosuppressants and is used to treat Asthma - Maintenance and Urticaria.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R03DX05

CAS registry number (Chemical Abstracts Service)

0242138-07-4

Chemical Formula

C6450-H9916-N1714-O2023-S38

Molecular Weight

145058

Therapeutic Categories

Antiasthmatic agent

Antiallergic agent

Immunomodulator

Monoclonal antibody

Chemical Name

Immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clone psVIE26 gamma-chain), disulfide wit human-mouse monoclonal E25 clone psVIE26 *k63-chain, dimer (WHO)

Foreign Names

  • Omalizumabum (Latin)
  • Omalizumab (German)
  • Omalizumab (French)
  • Omalizumab (Spanish)

Generic Names

  • Omalizumab (OS: BAN, USAN)
  • Omalizumab (Genetical Recombination) (OS: JAN)
  • AL 901 (IS)
  • anti-Ig E (IS)
  • CGP 51901 (IS)
  • E25 (IS)
  • Humanized anti-IgE monoclonal antibody (IS)
  • IGE 025 (IS)
  • Monoclonal antibody E25 (IS)
  • Monoklonaler Anti-Ig E Antik├Ârper, human, rekombiniert (IS)
  • Monoklonaler Antik├Ârper E25 (IS)
  • Olizumab (IS)
  • psVIE26 *k63-chain, dimer (IS: WHO)
  • Recombinant humanized anti-IgE monoclonal antibody (IS)
  • rhu MAb-E25 (IS)
  • TNX 901 (IS)

Brand Names

  • Xolair
    Genentech, United States; Grupo Novartis, Spain; Novartis, Argentina; Novartis, Belgium; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Denmark; Novartis, Ecuador; Novartis, Egypt; Novartis, Finland; Novartis, France; Novartis, Georgia; Novartis, Greece; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Iceland; Novartis, Japan; Novartis, Lebanon; Novartis, Lithuania; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Serbia; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Turkey; Novartis, Taiwan; Novartis Biosciences, Peru; Novartis Europharm, Austria; Novartis Farma, Italy; Novartis Healthcare, Philippines; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharma, Russian Federation; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide